Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


Articles published in Curr Opin Obstet Gynecol

Retrieve available abstracts of 7 articles:
HTML format
Text format



Single Articles


    November 2018
  1. WINTERHOFF B, Talukdar S, Chang Z, Wang J, et al
    Single-cell sequencing in ovarian cancer: a new frontier in precision medicine.
    Curr Opin Obstet Gynecol. 2018 Nov 30. doi: 10.1097/GCO.0000000000000516.
    PubMed     Text format     Abstract available


  2. WASHINGTON C, Gunderson CC, Moore KN
    Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research.
    Curr Opin Obstet Gynecol. 2018 Nov 15. doi: 10.1097/GCO.0000000000000507.
    PubMed     Text format     Abstract available


    February 2018
  3. MCCANN KE
    Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
    Curr Opin Obstet Gynecol. 2018;30:7-16.
    PubMed     Text format     Abstract available


  4. VOLPE J, Filipi JG, Cooper OR, Penson RT, et al
    Frontline therapy of ovarian cancer: trials and tribulations.
    Curr Opin Obstet Gynecol. 2018;30:1-6.
    PubMed     Text format     Abstract available


    November 2017
  5. PALEARI L, DeCensi A
    Endocrine therapy in ovarian cancer: where do we stand?
    Curr Opin Obstet Gynecol. 2017 Nov 14. doi: 10.1097/GCO.0000000000000423.
    PubMed     Text format     Abstract available


    November 2016
  6. KROEGER PT JR, Drapkin R
    Pathogenesis and heterogeneity of ovarian cancer.
    Curr Opin Obstet Gynecol. 2016.
    PubMed     Text format     Abstract available


    February 2016
  7. WALSH CS, Hodeib M
    Leveraging DNA repair deficiency in gynecologic oncology.
    Curr Opin Obstet Gynecol. 2016;28:24-31.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: